Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
Total Valuation
Protagonist Therapeutics has a market cap or net worth of $6.17B. The enterprise value is $6.06B.
Market Cap$6.17B
Enterprise Value$6.06B
Share Statistics
Protagonist Therapeutics has 63,808,716 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63,808,716
Owned by Insiders1.33%
Owned by Institutions11.64%
Financial Efficiency
Protagonist Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -25.23%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.19
Return on Invested Capital (ROIC)-25.23%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee371.10K
Profits Per Employee0.00
Employee Count124
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Protagonist Therapeutics is ―. Protagonist Therapeutics’s PEG ratio is 0.29.
PE Ratio―
PS Ratio120.66
PB Ratio9.03
Price to Fair Value9.03
Price to FCF99.01
Price to Operating Cash Flow106.65
PEG Ratio0.29
Income Statement
In the last 12 months, Protagonist Therapeutics had revenue of 46.02M and earned -130.15M in profits. Earnings per share was -2.05.
Revenue46.02M
Gross Profit44.79M
Operating Income-158.13M
Pretax Income-129.31M
Net Income-130.15M
EBITDA-128.09M
Earnings Per Share (EPS)-2.05
Cash Flow
In the last 12 months, operating cash flow was 57.67M and capital expenditures 0.00, giving a free cash flow of 57.67M billion.
Operating Cash Flow57.67M
Free Cash Flow57.67M
Free Cash Flow per Share0.90
Dividends & Yields
Protagonist Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change82.51%
50-Day Moving Average85.93
200-Day Moving Average71.77
Relative Strength Index (RSI)62.43
Average Volume (3m)633.14K
Important Dates
Protagonist Therapeutics upcoming earnings date is May 6, 2026, After Close (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
Protagonist Therapeutics as a current ratio of 12.71, with Debt / Equity ratio of 1.68%
Current Ratio12.71
Quick Ratio12.71
Debt to Market Cap<0.01
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Protagonist Therapeutics has paid 838.00K in taxes.
Income Tax838.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Protagonist Therapeutics EV to EBITDA ratio is -42.43, with an EV/FCF ratio of 96.90.
EV to Sales118.10
EV to EBITDA-42.43
EV to Free Cash Flow96.90
EV to Operating Cash Flow94.23
Balance Sheet
Protagonist Therapeutics has $567.36M in cash and marketable securities with $10.32M in debt, giving a net cash position of $557.04M billion.
Cash & Marketable Securities$567.36M
Total Debt$10.32M
Net Cash$557.04M
Net Cash Per Share$8.73
Tangible Book Value Per Share$9.67
Margins
Gross margin is 99.18%, with operating margin of -343.63%, and net profit margin of -282.83%.
Gross Margin99.18%
Operating Margin-343.63%
Pretax Margin-281.01%
Net Profit Margin-282.83%
EBITDA Margin-278.35%
EBIT Margin-281.01%
Analyst Forecast
The average price target for Protagonist Therapeutics is $104.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$104.67
Price Target Upside8.19% Upside
Analyst ConsensusStrong Buy
Analyst Count10
Revenue Growth Forecast-35.39%
EPS Growth Forecast-72.97%